Vera Therapeutics Files 8-K on Shareholder Vote Matters

Ticker: VERA · Form: 8-K · Filed: May 19, 2025 · CIK: 1831828

Vera Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyVera Therapeutics, INC. (VERA)
Form Type8-K
Filed DateMay 19, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: shareholder-vote, corporate-governance

TL;DR

Vera Therapeutics held a shareholder vote on May 14th, details filed today.

AI Summary

Vera Therapeutics, Inc. filed an 8-K on May 19, 2025, reporting on matters submitted to a vote of security holders on May 14, 2025. The filing details the company's corporate information, including its principal executive offices in Brisbane, California, and its standard industrial classification in Pharmaceutical Preparations.

Why It Matters

This filing indicates that Vera Therapeutics held a vote of its security holders, which could pertain to significant corporate decisions or governance changes.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain information about significant financial events or operational changes.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of Vera Therapeutics' security holders on May 14, 2025?

The filing states that matters were submitted to a vote of security holders on May 14, 2025, but does not specify the exact nature of these matters in the provided text.

When was Vera Therapeutics, Inc. incorporated?

Vera Therapeutics, Inc. was incorporated in Delaware, as indicated by the filing.

What is Vera Therapeutics' primary business classification?

Vera Therapeutics, Inc. is classified under Pharmaceutical Preparations [2834].

What is the SEC file number for Vera Therapeutics?

The SEC file number for Vera Therapeutics is 001-40407.

Where are Vera Therapeutics' principal executive offices located?

Vera Therapeutics' principal executive offices are located at 2000 Sierra Point Parkway, Suite 1200, Brisbane, California 94005.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 19, 2025 regarding Vera Therapeutics, Inc. (VERA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing